India Globalization Capital Inc. (IGC)
Symbol Info
Listed Symbol IGC
Name India Globalization Capital Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2019-03-31
Latest Fiscal Revenue $5,115,540
Latest Fiscal EPS $-0.14
Price Info
21 Day Moving Average $1.0840
21 Day EMA $1.105200
50 Day Moving Average $1.1944
50 Day EMA $1.168200
200 Day EMA $1.287920
200 Day Moving Average 1.202500
52 Week High $14.58
52 Week Low $0.25
52 Week Change $-0.925900
Alpha 0.123168
Beta 6.4953
Standard Deviation 0.937991
R2 0.056978
Periods 60
Share Information
10 Day Average Volume 430,938
20 Day Average Volume 391,446
30 Day Average Volume 362,115
50 Day Average Volume 396,764
Outstanding Shares 39,511,407
Float Shares 32,687,099
Percent Float 82.73%
Short Interest 1,028,170
Short Percent Float 2.60%
Short Interest Ratio 3.40
Short Date 2019-08-30
Holders
Institutions 31
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 179,855
Institute Holdings Percent 4.400000
Institute Sold Previous 3 Months 51,811
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 7
Insider Holdings Percent 17.30%
Insider Sold Previous 3 Months -
Insiders Shares Owned 6,824,308
Price Change
7 Day Price Change $-0.0401
7 Day Percent Change -3.61%
21 Day Price Change $0.0400001
21 Day Percent Change 3.88%
30 Day Price Change $0.0100001
30 Day Percent Change 0.94%
Month To Date Price Change $0.0400
Month To Date Percent 3.88%
90 Day Price Change $-0.13
90 Day Percent Change -10.83%
Quarter To Date $-0.57
Quarter To Date Percent -34.76%
180 Day Price Change $-1.18
180 Day Percent Change -52.44%
200 Day Price Change $-1.73
200 Day Percent Change -61.79%
Year To Date $0.790000
Year To Date Percent 282.14%
Profile
Description India Globalization Capital Inc is engaged in the development of cannabis-based combination therapies to treat Alzheimer's, pain, nausea, eating disorders, several endpoints of Parkinson's, and epilepsy in humans, dogs, and cats. The company has focused on four products that it is preparing for medical trials, Natrinol, Caesafin, Serosapse, and Hyalolex.
Details
Issue Type CS
Market Cap $42,672,320
Sec Type EQS
Auditor Manohar Chowdhry & Associates
Total Shares Outstanding 39,511,407
CEO Ram Mukunda
Employees 20
Last Audit UQ
Classification
CIK 0001326205
Industry Drug Manufacturers
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 12224 Falls Road
Potomac, MD 20854
Website https://www.igcinc.us
Facisimile
Telephone +1 301 983-0998
Email info@igcinc.us
Key Ratios
Profitability
EBIT Margin -105.7
EBITDA Margin -104.5
Pre-Tax Profit Margin -116.7
Profit Margin Cont -93.87
Gross Margin 2.50
Profit Margin TOT -93.87
Income Statements
Revenue $5,287,000
Revenue Per Share $0.1338
Revenue 3 Years $25.12
Revenue 5 Years $-1.83
Valuation Measures
PE Ratio -
Enterprise Value $22,739,775
Price To Sales 7.996445
Price To Free Cash -6.4
PE High Last 5 Years -
Price To Book 1.4
Price To Cash Flow 13.0
PE Low Last 5 Years -
Price To Tangible Book 1.4
Financial Strength
Total Debt To Equity -
Int Coverage -
Current Ratio 23.0
Leverage Ratio 1.0
Quick Ratio 20.3
Long Term Debt To Capital -
Assets
Receivables Turnover 2.1
Invoice Turnover 3.90
Assets Turnover 0.10
Management Effectiveness
Return Assets -22.05
Return On Equity -24.82
Return On Capital -23.72
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
AMEX
IGC
India Glob..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.